Skip to content

Study · Non-randomized trial · 2009

6 results

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Dec 2009Cited by 41 (Europe PMC)

PMID19453263 (opens in a new tab)DOI10.1359/jbmr.090527 (opens in a new tab)PepBankPUB-19453263
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal women previously treated with alendronate, crack density decreased during teriparatide treatment.

    In plain wordsIn women previously treated with alendronate, bone crack density decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCrack density after prior alendronate
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal women previously treated with alendronate, crack surface density decreased during teriparatide treatment.

    In plain wordsIn women previously treated with alendronate, bone crack surface density decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCrack surface density after prior alendronate
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal women previously treated with alendronate, crack length decreased during teriparatide treatment.

    In plain wordsIn women previously treated with alendronate, bone crack length decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCrack length after prior alendronate
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.
  4. 04HumanNon-randomized trialEfficacy outcome

    In previously untreated postmenopausal women, crack length decreased during teriparatide treatment.

    In plain wordsIn previously untreated women, bone crack length decreased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCrack length in previously untreated patients
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.
  5. 05HumanNon-randomized trialEfficacy outcome

    In previously untreated postmenopausal women, crack density did not decrease during teriparatide treatment.

    In plain wordsIn previously untreated women, bone crack density did not decrease during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCrack density in previously untreated patients
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.
  6. 06HumanNon-randomized trialEfficacy outcome

    In previously untreated postmenopausal women, crack surface density did not decrease during teriparatide treatment.

    In plain wordsIn previously untreated women, bone crack surface density did not decrease during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCrack surface density in previously untreated patients
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    After 24 mo of teriparatide treatment, crack density (Cr.Dn), crack surface density (Cr.S.Dn), and crack length (Cr.Le) were decreased in previously alendronate-treated patients, whereas only Cr.Le was reduced in former treatment-naïve patients.
    2 context sentences
    Summary · context
    Sixty-six postmenopausal women with osteoporosis (mean age, 68.0 yr; and mean BMD T-score of -2.8 at lumbar spine and -1.7 at total hip; 62% with prevalent fractures) entered this prospective, nonrandomized study and started with 24-mo 20 microg/d subcutaneous teriparatide treatment in monotherapy:
    Summary · context
    Thirty-one paired biopsies with two intact cortices were collected and analyzed for microstructure and microdamage accumulation at baseline and after 24 mo of teriparatide administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.